Age-Related Changes in Bone Marrow Clonal Architecture

Abstract

Ageing is accompanied by progressive remodeling of the hematopoietic stem and progenitor cell compartment, resulting in measurable changes in bone marrow clonal architecture. These changes include reduced stem-cell diversity, expansion of clones with relative fitness advantages, altered lineage output, and increasing prevalence of somatic mutations associated with clonal hematopoiesis. Clonal hematopoiesis of indeterminate potential, commonly defined by the presence of an acquired myeloid-associated mutation at a detectable variant allele fraction in the absence of overt hematologic malignancy, is frequent in older adults and is increasingly recognized as a clinically relevant biological state rather than an incidental molecular finding. Age-related clonal expansion is shaped by replicative stress, inflammatory signaling, impaired DNA repair, altered marrow niches, and selective pressures imposed by infection, smoking, cytotoxic exposure, and chronic disease. Although most individuals with clonal hematopoiesis never develop leukemia or another myeloid neoplasm, specific mutations, larger clone size, multiple cooperating abnormalities, cytopenias, and adverse clinical context increase the likelihood of progression. Clonal hematopoiesis is also associated with cardiovascular disease, chronic inflammation, and selected solid tumors. This review summarizes the epidemiology, mechanisms, clinical manifestations, diagnostic approach, management principles, emerging therapies, and practical guideline-based considerations relevant to age-related changes in bone marrow clonal architecture.

Introduction

Bone marrow hematopoiesis is maintained by a complex pool of hematopoietic stem cells that continuously balances self-renewal, differentiation, and preservation of genomic integrity. In early life, hematopoietic output is supported by a relatively diverse stem-cell population. With advancing age, the number and functional heterogeneity of active stem-cell clones change. Some clones become preferentially expanded because they acquire somatic mutations that enhance self-renewal, improve resistance to stress, or alter interactions with the marrow microenvironment. The resulting process is termed clonal hematopoiesis and represents an important biological feature of normal ageing, although it can also constitute a precursor state for myeloid malignancy.

Modern sequencing has demonstrated that age-related clonal architecture is more dynamic than previously recognized. Mutations may arise decades before clinical disease, remain stable, or expand rapidly under selective pressure. The clinical challenge is to distinguish benign or low-risk age-associated clonal hematopoiesis from clones that signal occult marrow dysfunction or substantial risk of progression. This distinction requires integration of molecular findings with blood counts, peripheral smear examination, medical history, physical examination, and, when indicated, bone marrow assessment. For clinicians, interpretation should focus not only on whether a mutation is present but also on the affected gene, variant allele fraction, number of abnormalities, trajectory over time, and associated clinical phenotype.

Epidemiology / Disease Burden

Clonal hematopoiesis becomes increasingly common with age and is uncommon in children and young adults unless associated with inherited predisposition or prior cytotoxic treatment. Population studies using targeted sequencing or broader genomic assays have shown that detectable clonal hematopoiesis is present in a substantial minority of adults in later decades of life, with prevalence estimates varying according to assay sensitivity, gene panel composition, variant allele threshold, and the definition used. The most frequently implicated genes include DNMT3A, TET2, and ASXL1, although mutations involving splicing factors, signaling pathways, and tumor suppressor genes may carry different biological and clinical implications.

The burden of clonal hematopoiesis extends beyond progression to acute myeloid leukemia, myelodysplastic syndromes, or myeloproliferative neoplasms. Associations have been reported with atherosclerotic cardiovascular disease, heart failure, chronic inflammatory conditions, and adverse outcomes after selected systemic therapies. These relationships are particularly notable for mutations affecting inflammatory pathways, although causality and the degree of risk differ among genes and patient populations. Clonal hematopoiesis may therefore represent both a marker of biological ageing and a contributor to age-related disease. The absolute risk for an individual remains heterogeneous, and most carriers do not develop an overt hematologic malignancy.

Pathophysiology

Age-related clonal architecture results from the interaction of genetic evolution and environmental selection. Hematopoietic stem cells accumulate somatic mutations through endogenous replication errors, oxidative stress, defective DNA repair, and exposure to genotoxic agents. Most mutations are biologically neutral or deleterious and disappear through cellular attrition. A minority confer a competitive advantage, allowing the affected clone to produce a disproportionate share of circulating blood cells. Mutations in epigenetic regulators such as DNMT3A and TET2 can alter DNA methylation, chromatin organization, transcriptional programs, and self-renewal behavior. ASXL1 alterations may disrupt chromatin regulation and are often associated with less favorable clinical biology.

The marrow niche also changes with age. Stromal cells, endothelial cells, adipocytes, extracellular matrix components, and immune populations influence stem-cell retention and differentiation. Increased inflammatory signaling, including activity within interleukin and tumor necrosis factor pathways, may favor clones capable of tolerating chronic stress. Experimental and translational studies suggest that inflammatory cytokines can create reciprocal reinforcement: an expanded clone promotes inflammatory signaling, while inflammation provides a selective environment for the clone. Therapy-related selection is another important mechanism. Prior chemotherapy or radiotherapy may eliminate susceptible stem cells and permit expansion of resistant clones, particularly those with defects in DNA damage response pathways.

Clonal architecture is not static. A patient may harbor several clones with distinct mutations, different lineage contributions, and unequal growth rates. Subclonal diversification can occur through acquisition of cooperating mutations, leading to ineffective hematopoiesis, dysplasia, excess blast production, or overt neoplasia. Conversely, a clone may remain stable for many years. The tempo of evolution depends on mutation identity, clone size, genomic complexity, host immunity, marrow injury, and the presence of inherited susceptibility.

Risk Factors

Chronological age is the dominant risk factor, but age-associated clonal expansion is modified by multiple exposures and host characteristics. Tobacco use, prior chemotherapy, radiation exposure, chronic inflammatory disease, renal dysfunction, autoimmune disorders, and persistent infection have been associated with increased prevalence or expansion of clonal hematopoiesis in various studies. Germline predisposition syndromes involving DNA repair, telomere maintenance, or myeloid malignancy susceptibility may lead to earlier onset or unusual mutation patterns. Family history of myeloid neoplasia should therefore be considered, particularly in younger patients or those with unexplained cytopenias.

Cardiovascular risk factors such as diabetes, hypertension, obesity, dyslipidemia, and chronic kidney disease may coexist with clonal hematopoiesis and complicate interpretation of associated outcomes. These comorbidities should not automatically be attributed to clonal mutations, because confounding by age and inflammation is substantial. Nevertheless, their presence reinforces the importance of comprehensive risk assessment and prevention rather than narrow surveillance for leukemia alone.

Clinical Features

Most individuals with age-related clonal hematopoiesis are asymptomatic and have normal blood counts. The finding is often made incidentally during genomic testing performed for another indication. When clinical manifestations occur, they may reflect evolving marrow dysfunction, an associated inflammatory state, or a separate medical condition. Unexplained anemia, neutropenia, thrombocytopenia, macrocytosis, persistent monocytosis, or abnormalities in multiple blood-cell lineages should prompt evaluation for clonal cytopenia or an established myeloid neoplasm rather than being labeled uncomplicated clonal hematopoiesis.

Patients with overt progression may develop fatigue, recurrent infections, bruising, bleeding, constitutional symptoms, splenomegaly, or symptoms related to leukocytosis and hyperviscosity. Cardiovascular manifestations are not specific and should be evaluated using standard clinical pathways. The presence of a mutation does not establish that it is responsible for an individual symptom, and clinical correlation remains essential.

Diagnosis

Diagnostic evaluation begins with confirmation of persistent blood-count abnormalities, review of prior complete blood counts, medication and exposure history, family history, and examination for organomegaly or systemic disease. Peripheral blood next-generation sequencing can identify somatic variants and estimate variant allele fraction, but technical sensitivity, coverage, and reporting thresholds differ between laboratories. A molecular result should be interpreted in the context of the affected gene and the possibility of germline variation, especially when the variant is present at a high allele fraction or when personal and family history suggests inherited predisposition.

Clonal hematopoiesis generally describes a detectable clone without unexplained cytopenias or diagnostic criteria for a hematologic malignancy. When cytopenias are present, the appropriate category may be clonal cytopenia of undetermined significance, myelodysplastic syndrome, or another marrow disorder, depending on morphology, cytogenetics, blast percentage, and clinical findings. Bone marrow aspiration and biopsy are appropriate for unexplained or progressive cytopenias, abnormal blood films, substantial or rapidly increasing clone size, multiple high-risk mutations, or concern for an established neoplasm. Cytogenetic studies and flow cytometry may provide complementary information.

Treatment & Management

There is no universally approved mutation-directed treatment for asymptomatic clonal hematopoiesis. Management should be individualized according to clone characteristics, blood counts, age, comorbidities, family history, and patient preferences. For low-risk findings with normal counts, periodic clinical review and complete blood counts are generally appropriate. The interval should reflect the molecular profile and clinical context rather than a rigid schedule. Repeat sequencing may be useful when blood counts change, symptoms develop, or a clone appears to be expanding, but routine frequent testing without a clinical indication can increase anxiety and may not alter management.

Preventive care is central. Clinicians should address smoking cessation, blood pressure, diabetes, lipid abnormalities, physical inactivity, obesity, and other modifiable cardiovascular risks. Standard cancer screening and age-appropriate vaccination should continue. Patients should be advised to report persistent fever, recurrent infection, unusual bruising, bleeding, progressive fatigue, or unexplained weight loss. Hematology referral is appropriate for persistent cytopenias, high-risk mutations, multiple abnormalities, increasing variant allele fraction, or uncertainty regarding the distinction between clonal hematopoiesis and myeloid neoplasia.

Patients receiving chemotherapy, radiotherapy, stem-cell transplantation, or other marrow-toxic treatment require special consideration. Pre-existing clones may expand after therapy and can complicate interpretation of post-treatment cytopenias. Treatment decisions should remain based on the primary disease and established clinical indications; the mere presence of clonal hematopoiesis is not, by itself, a reason to withhold effective therapy.

Recent Advances / Emerging Therapies

Recent advances include increasingly sensitive sequencing methods, longitudinal clonal tracking, single-cell genomic and transcriptomic analysis, and integration of molecular data with epigenetic, immunologic, and clinical variables. These approaches are clarifying how distinct clones occupy different marrow niches and why some mutations expand only after inflammatory or cytotoxic stress. Risk models incorporating mutation type, clone size, number of mutations, cytopenias, and red-cell indices may improve prediction of progression, although external validation and standardization remain necessary.

Therapeutic research is exploring strategies directed at inflammation, mutant stem-cell fitness, and cardiovascular consequences. Potential approaches include modulation of interleukin signaling, alteration of innate immune pathways, and selective targeting of vulnerabilities associated with specific mutations. Anti-inflammatory and lipid-lowering therapies are being studied in relation to cardiovascular risk, but evidence is not yet sufficient to prescribe medication solely because clonal hematopoiesis is present. Future interventions may involve preventive treatment for carefully selected high-risk individuals before overt myeloid malignancy develops. Such strategies must balance uncertain benefit against toxicity, cost, overdiagnosis, and the possibility of disrupting stable, clinically harmless clones.

Guideline Recommendations

Current expert guidance emphasizes that clonal hematopoiesis should be diagnosed and managed through multidisciplinary clinical interpretation rather than molecular testing alone. Patients with normal blood counts and low-risk molecular findings generally require observation, primary-care risk-factor management, and periodic blood-count monitoring. Hematology consultation is recommended for unexplained cytopenias, concerning morphology, high-risk or multiple mutations, large or rapidly expanding clones, abnormal cytogenetics, or suspected germline predisposition. Bone marrow examination should be used when it can resolve diagnostic uncertainty or assess possible progression.

Guideline-consistent care also includes documentation of the specific mutation, assay characteristics, variant allele fraction, blood-count trajectory, and relevant exposures. Genetic counseling should be considered when findings suggest inherited susceptibility, particularly in younger patients or families with multiple cases of myeloid malignancy. Communication should be clear that clonal hematopoiesis is a risk state, not synonymous with cancer. Surveillance plans should be documented and reassessed when clinical circumstances change.

Conclusion

Age-related changes in bone marrow clonal architecture reflect a continuous evolutionary process driven by somatic mutation, stem-cell selection, inflammatory signaling, and remodeling of the marrow niche. Clonal hematopoiesis is common in older adults and usually remains clinically silent, but selected molecular and hematologic features identify individuals at increased risk for myeloid malignancy and potentially for cardiovascular complications. Accurate management requires integration of genomic findings with blood counts, morphology, comorbidities, exposures, and longitudinal change. At present, surveillance, prompt evaluation of cytopenias, hematology referral for higher-risk features, and aggressive management of conventional cardiovascular risks represent the most evidence-aligned approach. Continued research into clonal biology and targeted prevention may eventually enable individualized interventions before malignant transformation occurs.